KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Total Liabilities (2016 - 2025)

Alnylam Pharmaceuticals' Total Liabilities history spans 17 years, with the latest figure at $4.2 billion for Q4 2025.

  • For Q4 2025, Total Liabilities changed 0.1% year-over-year to $4.2 billion; the TTM value through Dec 2025 reached $4.2 billion, changed 0.1%, while the annual FY2025 figure was $4.2 billion, 0.1% changed from the prior year.
  • Total Liabilities reached $4.2 billion in Q4 2025 per ALNY's latest filing, down from $4.6 billion in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $4.6 billion in Q3 2025 to a low of $2.3 billion in Q1 2021.
  • Average Total Liabilities over 5 years is $3.7 billion, with a median of $3.9 billion recorded in 2023.
  • Peak YoY movement for Total Liabilities: surged 150.47% in 2021, then increased 0.1% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $3.1 billion in 2021, then grew by 21.26% to $3.7 billion in 2022, then rose by 9.34% to $4.1 billion in 2023, then increased by 3.02% to $4.2 billion in 2024, then increased by 0.1% to $4.2 billion in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Total Liabilities are $4.2 billion (Q4 2025), $4.6 billion (Q3 2025), and $4.3 billion (Q2 2025).